Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial

Table 4 Regimens and results of salvage treatment for local recurrent or residual squamous cell carcinoma of the esophagus

Patient	Response for CCRT	Time to treatment failure (months)	Salvage treatment	Outcome	Duration ^# (months)	Survival from CCRT (months)
Residual cancer group
1	SD	12.40	TP→FOLFIRI	Dead of disease	54.90	73.30
Local failure at primary site group
2	PR	13.40	TP	Dead of disease	0.30	13.80
3	SD	77.43	TP + Radiotherapy	Dead of disease	28.93	108.20
4	PR	83.53	S-1 + Apatinib	Dead of disease	23.10	107.07
5	CR	20.77	Capecitabine	Dead of disease	13.27	34.17
6	CR	27.80	Surgery	Dead of disease	54.97	83.20
7	CR	14.90	TP + Surgery	Dead of disease	10.63	26.27
8	PR	137.23	S-1	Alive with disease	0.70	138.27
9	PR	10.07	Surgery	Dead of disease	12.17	23.63
10	PR	22.13	TP	Dead of disease	8.90	31.43
11	CR	27.43	Radiotherapy + S-1→TP + anti-PD-1 antibody→ Radiotherapy	Dead of disease	37.13	65.37
12	PR	6.40	Capecitabine	Dead of disease	13.50	20.03
13	PR	12.00	surgery	Alive, disease free	74.60	89.60
14	CR	51.40	TP + Radiotherapy	Alive, disease free	35.47	89.10
Metachronous multiple cancer group
15	CR	49.73	Radiotherapy + Capecitabine	Alive, disease free	80.27	131.27

^# The duration was measured from the date of salvage treatment to the date of confirmation of death or the end of follow-up
Abbreviations: CCRT = concurrent chemoradiotherapy; SD = stable disease; PR = partial response; CR = complete response; TP = taxol + platinum; FOLFIRI = 5-fluorouracil + irinotecan + leucovorin; anti-PD-1 = anti-program death-1

ISSN: 1748-717X